Comparison · NCT02175225-00a28ffd
Deferoxamine Mesylate vs Normal Saline: Number of Subjects With Serious Adverse Events Within 7 Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Deferoxamine Mesylate vs Normal Saline: Number of Subjects With Serious Adverse Events Within 7 Days. Trial comparisons, record NCT02175225-00a28ffd. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02175225-00a28ffd
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.115 | 0.236 | wilson | |
| Risk in group 2 | 0.177 | 0.124 | 0.247 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0102 | -0.0972 | 0.0772 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.942 | 0.569 | 1.56 | log | |
| Odds ratio, group 1 over group 2 | 0.931 | 0.506 | 1.71 | log | |
| Number needed to treat, for one fewer participant with the outcome on Deferoxamine Mesylate than on Normal Saline | 98 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Deferoxamine Mesylate | Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days~Deferoxamine Mesylate | 24 | 144 | OG000 |
| Group 2 | Normal Saline | Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days~Placebo (for Deferoxamine Mesylate) | 26 | 147 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Subjects With Serious Adverse Events Within 7 Days
- Description
- Number of Subjects Experiencing Serious Adverse Events within 7 days of randomization
- Time frame
- 7 days
- Population
- Per the SAP, the target population is the modified intention-to-treat population, including only subjects in whom study infusion is initiated.
Source ClinicalTrials.gov
Trial
- Title
- Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
- NCT number
- NCT02175225
- Phases
- PHASE2
- Conditions
- Intracerebral Hemorrhage
- Interventions
- Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate)
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Results first posted
- 2019-05-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02175225?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02175225-00a28ffd